血清CEA与CYFRA21-1检测对肺癌诊断价值的探讨

Evaluation of Serum CEA and CYFRA21-1 in Patients with Diagnosis Value of Lung Cancer

目的测定肺癌患者血清细胞角蛋白19片段(CEFRA21-1)及癌胚抗原(CEA)浓度,探讨其在肺癌诊断中的临床价值。方法对87例确诊肺癌患者和60例肺良性疾病患者测定CYFRA21-1及CEA水平并进行分析。结果肺癌患者血清CEA与CYFRA21-1水平显著高于肺良性疾病患者。CEA在腺癌的敏感性为61.9%,CYFRA21-1在鳞癌的敏感性为79.1%。CEA及CYFRA21-1对非小细胞肺癌的敏感性随临床分期升高而升高。结论CEA及CYFRA21-1是较好的非小细胞肺癌肿瘤标志物,CEA较适用于腺癌,CYFRA21-1较适用于鳞癌,其敏感性是监测肺癌病情的良好指标。

Objective To set the serum concentrations of CYFRA21-1 and CEA,and to evaluate the clinical usefulness of them as the tumor markers of lung cancer. Methods The levels of CYFRA21-1 and CEA were measured and analyzed in the serum of 87 patients with lung cancer,60 patients with benign lung diseases. Results Serum concentrations of CEA and CYFRA21-1 in patients with lung cancer were significantly higher than those with benign lung diseamses. Its sensitivity of CEA for lung cancer was 61.9% ,its sensitivity of CYFRA21-1 for squaous carcinoma was 79.1%. The sensitivity of serum CEA and CYFRA21-1 in non-small cell lung cancer increased with the advancement of clinical stages. Conclusion CEA and CYFRA21-1 are the sensitive and specific tumor markers of non-small cell lung cancer, CEA is for lung cancer, CYFRA21-1 is for squamous carcinoma,whose sesitivity are the good indexes in monitoring patients＇ condition for lung cancer.